tirzepatide surpass 2 SURPASS-2: bests semaglutide in HbA1c reduction, weight loss SURPASS‑EARLY evaluated starting tirzepatide early

Understanding each mechanism individually helps you target the right solution instead of guessing

This pricing covers the medication, compounding expertise, cold-chain shipping, and access to your provider

Novo Nordisk Announces Positive Results from Phase 3 ESSENCE Trial of Semaglutide Novo Nordisk announces positive results from phase 3 ESSENCE trial of semaglutide 2.4 mg to treat adults with MASH and liver fibrosis Overview Novo Nordisk, a leading global healthcare company, announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)

The variable testing standards and limited federal oversight of 503A pharmacies create uneven quality assurance across the thousands of pharmacies now compounding GLP-1 medications